Key result
Selective iNOS inhibitor GED significantly improves survival in preclinical lethal endotoxin shock.
Why the study?
Guanidinoethyldisulphide (GED) is a novel inhibitor of nitric oxide synthases with potential selectivity towards inducible NOS, but its pharmacological properties and therapeutic effects in inflammatory conditions were not fully characterized.
GED is a selective iNOS inhibitor that prevents vascular hyporeactivity and improves survival in animal models of endotoxin shock.
No takes yet. Share an insight, caveat, or question.
GED inhibits NOS in vitro; leaves open any clinical role in cardiovascular disease pending in vivo studies.
Szabó et al. (1996) studied Endotoxin shock. Guanidinoethyldisulphide (GED) vs. Control was evaluated on Survival rate in a lethal model of endotoxin shock in mice. Guanidinoethyldisulphide (GED) is a competitive, selective inhibitor of inducible nitric oxide synthase that significantly improved survival in a murine model of lethal endotoxin shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: